Abstract: A method for MR imaging that comprises conducting the MR imaging after injecting compositions that are chemical combination of porphyrins, chlorins, bacteriochlorins, and related tetra-pyrrolic compounds with radioactive elements such as Technetium99, Gadolinium, Indium111 and radioactive iodine. When the element can form cations, the compound is usually a chelate with the porphyrin or chlorin structure. When the element forms anions, the compound is usually a direct chemical combination of the radioactive element into the porphyrin or chlorin structure. The method uses the compounds of the invention for diagnostic imaging of hyperproliferative tissue such as tumors and new blood vessel growth as is associated with the wet form of age related macular degeneration and methods of making the compounds.
Type:
Grant
Filed:
March 17, 2003
Date of Patent:
July 18, 2006
Assignee:
Health Research, Inc.
Inventors:
Ravindra K. Pandey, Zachary Grossman, Peter Kanter, Thomas J. Dougherty
Abstract: Methods of and apparatus for preparing temperature activated gaseous precursor-filled liposomes are described. Gaseous precursor-filled liposomes prepared by these methods are particularly usefull for example, in ultrasonic imaging applications and in therapeutic drug delivery systems. Gas, gaseous precursors and perfluorocarbons are presented as novel potentiators for ultrasonic hyper-thermia. The gas, gaseous precursors and perfluorocarbons which may be administered into the vasculature, interstitially or into any body cavity are designed to accumulate in cancerous and diseased tissues. When therapeutic ultrasonic energy is applied to the diseased region heating is increased because of the greater effectiveness of sound energy absorption caused by these agents.
Abstract: A method for capturing specified materials which includes contacting a microporous material with a hydrostatic fluid having at least one specified material carried therein, under pressure which structurally distorts the lattice sufficiently to permit entry of the at least one specified material. The microporous material is capable of undergoing a temporary structural distortion which alters resting lattice dimensions under increased ambient pressure and at least partially returning to rest lattice dimensions when returned to ambient pressure. The pressure of the fluid is then reduced to permit return to at least partial resting lattice dimension while the at least one specified material is therein. By this method, at least one specified material is captured in the microporous material to form a modified microporous material.
Type:
Grant
Filed:
November 25, 2002
Date of Patent:
July 11, 2006
Assignee:
Brookhaven Science Associates, LLC
Inventors:
Thomas Vogt, Joseph A. Hriljac, Yongjae Lee
Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
Type:
Grant
Filed:
January 24, 2005
Date of Patent:
July 4, 2006
Assignee:
NeoRx Corporation
Inventors:
Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
Type:
Grant
Filed:
June 21, 2000
Date of Patent:
June 27, 2006
Assignee:
Board of Regents, University of Texas System
Inventors:
David J. Yang, Chun W. Liu, Dong-Fang Yu, E. Edmund Kim
Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a-moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.
Type:
Grant
Filed:
May 2, 2001
Date of Patent:
June 13, 2006
Assignee:
The Curators of the University of Missouri
Inventors:
Timothy J. Hoffman, Wynn A. Volkert, Gary Sieckman, Charles J. Smith, Hariprasad Gali
Abstract: A method of sensitizing tumor cells to radiation thereapy, chemotherapy and immunomodulatory thereapy, comprising the step of exposing the tumor cell to an effective amount of at least one monoterpene or sesquiterpene and treating the tumor cell is disclosed.
Type:
Grant
Filed:
November 7, 2001
Date of Patent:
June 6, 2006
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Michael N. Gould, Steven P. Howard, Deepika Rajesh
Abstract: The present invention relates to stabilized 99mTc radiopharmaceutical compositions, which include both a radioprotectant and one or more antimicrobial preservative(s), and hence have an extended lifetime of use. The radioprotectant is ascorbic acid, para-aminobenzoic acid, gentisic acid or a salt thereof with a biocompatible cation, and the antimicrobial preservative is one or more compound from the paraben series of preservatives. The invention is particularly useful for cationic, lipophilic 99mTc heart imaging agents such as Myoview™.
Type:
Grant
Filed:
April 11, 2001
Date of Patent:
May 30, 2006
Assignee:
GE Healthcare Limited
Inventors:
Alan Michael Forster, David Edwards, Ole Kristian Hjelstuen
Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
Type:
Grant
Filed:
July 18, 2003
Date of Patent:
May 30, 2006
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D Harris, Stuart D Heminway, Shuang Liu, Singh R Prahlad
Abstract: The present invention is directed to an Fe(III) complex comprising a redox-active metal cluster in a chemically inert shell. The inventive complex has electron transfer and paramagnetic properties.
Abstract: Stable isotope labeling and neutron activation to measure biological functions are provided, as are the use and method of adding a chemical monitor to correct for neutron flux to sample vials prior to the addition of sample is presented, and the use of stable isotopes as a chemical bar code for vials and other items. Methods are provided also for measuring glomerular filtration rate and glomerular sieving function in a subject, and for measuring other physiological functions.
Type:
Grant
Filed:
January 30, 2002
Date of Patent:
May 23, 2006
Assignee:
BioPhysics Assay Laboratory, Inc.
Inventors:
Ernest V. Groman, Christopher P. Reinhardt
Abstract: This invention relates to medical uses of radiopharmaceuticals. Specifically, the present invention relates to the use of radiopharmaceuticals to treat osteomyelitis. The present invention provides improved system and methods of for the direct delivery of radiopharmaceuticals to the site of osteomyelitis.
Type:
Grant
Filed:
December 11, 2002
Date of Patent:
May 16, 2006
Assignee:
Dow Global Technologies Inc.
Inventors:
Dana W. Simon, Alan D. Strickland, Jaime Simon, Daniel J. Macey, R. Keith Frank, Kenneth McMillan
Abstract: An agent which comprises, as an active ingredient, a radiolabeled compound as represented by the following formula or a pharmaceutically acceptable salt thereof: wherein R1 denotes hydrogen, or a linear- or branched-chain alkyl group having 1–8 carbon atoms, R2 denotes hydrogen, hydroxyl or a halogen substituent, R3 denotes hydrogen or fluorine substituent, R4 denotes oxygen, sulfur, or a methylene substituent, and R5 denotes a radioactive halogen substituent. The agent is stable in vivo, and either stays in cells or is incorporated in DNA, thus serving for diagnosis of tissue proliferation activity or treatment of proliferative disease.
Abstract: The present invention provides novel compounds comprising cellular phosphoinositides and analogues tagged with stable or radioactive isotopes. The present invention also provides novel methods for the preparation of the said phosphoinositides by syntheses, and novel key intermediates of synthesis; the novel methods of synthesis are applied also for the preparation of the phosphoinositides in non-labelled form. In addition, the present invention discloses a class of novel compounds as isotope labelled key precursors of labelled phosphoinositides. These precursors are derivatives of the target phosphoinositides, labelled with stable or radioactive isotopes, wherein OH and phosphate groups are blocked with temporary protecting groups.
Abstract: The method for diagnosing lactose intolerance in patients by the oral administration of defined amounts of lactose, followed by assaying metabolites of lactose, is performed in a way where the lactose administered contains 99% 13C-labeled lactose, preferably from 5 to 30 mg, and after the administration of the lactose, the content of 13C-labeled lactose is determined in a serum sample taken at a defined time after the administration. A diagnostic kit for performing the method consists of a capsule with from 5 to 30 mg of 99% 13C-labeled lactose, a patient instruction manual, a blood sampling device, sample containers for collecting the blood sample, and optionally a spatula and sample container for a stool specimen.
Abstract: This invention proposes the existence of an alternate glucose pathway different from that presently accepted and offers different methods of proving this. The proposed alternate glucose pathway considers the cerebral spinal fluid as a major component of the pathway. Based on this, a diagnostic tool for detecting mental disorders and neurological disorders which can not be detected by CT Scan and MRI is proposed. Medications directed at the CSF are also proposed.
Abstract: A polymeric solution capable of gelling upon exposure to a critical minimum value of a plurality of environmental stimuli is disclosed. The polymeric solution may be an aqueous solution utilized in vivo and capable of having the gelation reversed if at least one of the stimuli fall below, or outside the range of, the critical minimum value. The aqueous polymeric solution can be used either in industrial or pharmaceutical environments. In the medical environment, the aqueous polymeric solution is provided with either a chemical or radioisotopic therapeutic agent for delivery to a specific body part. The primary advantage of the process is that exposure to one environmental stimuli alone will not cause gelation, thereby enabling the therapeutic agent to be conducted through the body for relatively long distances without gelation occurring.
Abstract: A method of the administration of drugs with binding affinity for plasma protein and drugs regulating the effective ingredient dose of drugs with binding affinity for plasma protein; and a preparation whereby the effective ingredient dose of drugs with binding affinity for plasma protein is regulated. The above administration method is characterized in that, in the administration of a first drug having binding affinity for plasma protein, a second drug having binding affinity for the same plasma protein is administered simultaneously with the first drug or before or after the administration of the first drug to thereby regulate the binding of the first drug to the plasma protein.
Abstract: Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: wherein X is O or NR9 and Het, R1, R7, R8, R12—R15, Ra, Rb, Rc, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
November 17, 2003
Date of Patent:
April 18, 2006
Assignee:
Ortho-McNeil Pharmaceuticals, Inc.
Inventors:
Tianbao Lu, Bruce E. Tomczuk, Thomas P. Markotan, Colleen Siedem